Publications by authors named "Dylan Scott Eiger"

β-arrestins are multifunctional intracellular proteins that regulate the desensitization, internalization and signaling of over 800 different G protein-coupled receptors (GPCRs) and interact with a diverse array of cellular partners. Beyond the plasma membrane, GPCRs can initiate unique signaling cascades from various subcellular locations, a phenomenon known as "location bias". Here, we investigate how β-arrestins direct location-biased signaling of the angiotensin II type I receptor (AT1R).

View Article and Find Full Text PDF

The canonical paradigm of GPCR signaling recognizes G proteins and β-arrestins as the two primary transducers that promote GPCR signaling. Recent evidence suggests the atypical chemokine receptor 3 (ACKR3) does not couple to G proteins, and β-arrestins are dispensable for some of its functions. Here, we employed proximity labeling to identify proteins that interact with ACKR3 in cells devoid of β-arrestin.

View Article and Find Full Text PDF

Some G protein-coupled receptors (GPCRs) demonstrate biased signaling such that ligands of the same receptor exclusively or preferentially activate certain downstream signaling pathways over others. This phenomenon may result from ligand-specific receptor phosphorylation by GPCR kinases (GRKs). GPCR signaling can also exhibit location bias because GPCRs traffic to and signal from subcellular compartments in addition to the plasma membrane.

View Article and Find Full Text PDF
Article Synopsis
  • GPCRs are a large family of receptors that communicate signals through G proteins and β-arrestins, often leading to "biased" signaling where different pathways are activated to different extents.
  • One factor affecting this biased signaling is "location bias," which means that the receptor's cellular location can influence the type of signaling pathways activated.
  • The review examines how GPCRs are located and function in various parts of the cell, the implications of this for drug interactions, and how understanding location bias could lead to better therapies targeting GPCRs.
View Article and Find Full Text PDF

Some G protein-coupled receptor (GPCR) ligands act as "biased agonists" that preferentially activate specific signaling transducers over others. Although GPCRs are primarily found at the plasma membrane, GPCRs can traffic to and signal from many subcellular compartments. Here, we determine that differential subcellular signaling contributes to the biased signaling generated by three endogenous ligands of the GPCR CXC chemokine receptor 3 (CXCR3).

View Article and Find Full Text PDF
Article Synopsis
  • GPCRs are a major target for drugs, making up about one-third of FDA-approved medications, and they engage with various transducers like G proteins and β-arrestins.
  • Biased agonism is a key concept where certain ligands selectively activate specific pathways, which could lead to better drug designs that minimize side effects.
  • Despite its promise, only one biased GPCR drug has been approved, highlighting a need for a better understanding of how these pathways work together and a call for a systems pharmacology approach to improve drug development.
View Article and Find Full Text PDF

In the human chemokine system, interactions between the approximately 50 known endogenous chemokine ligands and 20 known chemokine receptors (CKRs) regulate a wide range of cellular functions and biological processes including immune cell activation and homeostasis, development, angiogenesis, and neuromodulation. CKRs are a family of G protein-coupled receptors (GPCR), which represent the most common and versatile class of receptors in the human genome and the targets of approximately one third of all Food and Drug Administration-approved drugs. Chemokines and CKRs bind with significant promiscuity, as most CKRs can be activated by multiple chemokines and most chemokines can activate multiple CKRs.

View Article and Find Full Text PDF